Top

Published in:

01-08-2014 | Original Paper

Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities

Authors: Dan Yoon, Irene Rusu, Irene Barbazetto

Published in: International Ophthalmology | Issue 4/2014

Abstract

This study investigated whether the presence of vitreomacular interface abnormalities (VMIAs) affects the improvement in visual acuity and edema of patients with diabetic macular edema (DME) who received three anti-vascular endothelial growth factor (VEGF) injections. Fifteen eyes of 11 patients with clinically significant macular edema were retrospectively divided into either the control group (only DME) or the experimental group (DME and VMIA) based on optical coherence tomography images. We defined VMIA patterns as epiretinal membrane and/or anomalous vitreomacular adhesion. Changes in central macular thickness (CMT), total macular volume (TMV), and best-corrected visual acuity (BCVA) from the baseline to post third injection were compared between the two groups. After the third injection, the decreases in CMT and TMV were not statistically different between the two groups. The improvement in BCVA was larger in the control group (0.1742 ± 0.0508 logMAR) than in the experimental group (0.0766 ± 0.0562 logMAR; p < 0.01). Our study showed that after the third anti-VEGF injection, the BCVA of patients with both DME and VMIAs improved significantly less than that of patients with only DME. Our results suggest that VMIAs may play a crucial role in reducing the therapeutic effects of anti-VEGF agents.

Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef

Chang CK, Cheng CK, Bai CH, Peng CH, Hu CC (2012) Development of vitreomacular interface abnormality in patients with diabetic macular edema. Taiwan J Ophthalmol 2:93–98CrossRef

Kim NR, Kim YJ, Chin HS, Moon YS (2009) Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation. Br J Ophthalmol 93:901–905PubMedCrossRef

Ghazi NG, Ciralsky JB, Shah SM, Campochiaro PA, Haller JA (2007) Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface. Am J Ophthalmol 144:747–754PubMedCrossRef

Group ETDRS (1985) Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806CrossRef

Kaiser PK, Riemann CD, Sears JE, Lewis H (2001) Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 131:44–49PubMedCrossRef

Nguyen QD, Brown DM, Marcus DM, et al RISE and RIDE Research Group (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology119:789–801

Rajendram R, Fraser-Bell S, Kaines A et al (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130:972–979PubMed

Wu PC, Lai CH, Chen CL, Kuo CN (2012) Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Th 28:59–64CrossRef

10.

Laidlaw DA (2008) Vitrectomy for diabetic macular oedema. Eye 22:1337–1341PubMedCrossRef

11.

Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A (2003) Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 135:169–177PubMedCrossRef

12.

Group ETDRS (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: early treatment diabetic retinopathy study report number 2. Ophthalmology 94:761–774CrossRef

13.

Wilkins JR, Puliafito CA, Hee MR, Duker JS, Reichel E, Coker JG et al (1996) Characterization of epiretinal membranes using optical coherence tomography. Ophthalmology 103:2142–2151PubMedCrossRef

14.

Ophir A, Martinez MR, Mosqueda P, Trevino A (2010) Vitreous traction and epiretinal membranes in diabetic macular oedema using spectral-domain optical coherence tomography. Eye 24:1545–1553PubMedCrossRef

15.

Lewis H, Abrams GW, Blamenkranz MS, Campo RV (1992) Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753–759PubMedCrossRef

16.

Kaiser PK, Riemann CD, Sears JE, Lewis H (2001) Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 131:44–49PubMedCrossRef

17.

Thomas D, Bunce C, Moorman C, Laidlaw AH (2005) Frequency and associations of a taut thickened posterior hyaloid, partial vitreomacular separation, and subretinal fluid in patients with diabetic macular edema. Retina 25:883–888PubMedCrossRef

18.

Gandorfer A, Messmer EM, Ulbig MW, Kampik A (2000) Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 20:126–133PubMedCrossRef

19.

Jumper JM, Embabi SN, Toth CA et al (2000) Electron immunocytochemical analysis of posterior hyaloid associated with diabetic macular edema. Retina 20:63–68PubMedCrossRef

20.

Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132:369–377PubMedCrossRef

21.

Chen Y, Hackett S, Schoenfeld C, Vinores M, Vinores S, Campochiaro P (1997) Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol 81:919–926PubMedCentralPubMedCrossRef

22.

Schneeberger SA, Hjelmeland LM, Tucker RP, Morse LS (1997) Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes. Am J Ophthalmol 124:447–454PubMed

23.

Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855–859PubMedCrossRef

24.

Appiah AP, Hirose T (1989) Secondary causes of premacular fibrosis. Ophthalmology 96:389–392PubMedCrossRef

25.

Mester U, Volker B, Kroll P, Berg P (1988) Complications of prophylactic argon laser treatment of retinal breaks and degenerations in 2,000 eyes. Ophthalmic Surg 19:482–484PubMed

Title: Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities
Authors: Dan Yoon
Irene Rusu
Irene Barbazetto
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 4/2014
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-013-9884-6

At a glance: The STEP trials

Springer Medicine

Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Reasons reported by African ophthalmologists for staying in Africa and for considering migrating

Vitreous hemorrhage secondary to retinal vasculopathy in a patient with dyskeratosis congenita

Treatment of myopic choroidal neovascularization with posterior sub-Tenon’s bevacizumab injection (Avastin®)

Atypical hydrops in keratoconus

Value of preoperative optical coherence tomography for predicting visual outcome after epiretinal membrane surgery

Cistoid macular edema as first manifestation of sarcoidosis